Lyra Therapeutics reports disappointing results for LYR-210 in Phase 3 chronic rhinosinusitis trial

Lyra Therapeutics, Inc. (Nasdaq: LYRA), dedicated to advancing treatments for chronic rhinosinusitis (CRS), announced that its Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 did not ... Read More